Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 117 | 133 | +16 |
| Shares | 57.4M | 62.3M | +4.93M (+8.6%) |
| Value | $550.5M | $733.6M | +$183.1M (+33.3%) |
New holders (27)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (11)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Schonfeld Strategic Advisors LLC | 306,399 | $2.94M |
| State of Wisconsin Investment Board | 90,781 | $870.6K |
| Diadema Partners LP | 40,294 | $386.4K |
| Nebula Research & Development LLC | 37,937 | $363.8K |
| Voya Investment Management LLC | 11,823 | $113.4K |
| Entropy Technologies, LP | 11,600 | $111.2K |
| ProShare Advisors LLC | 11,265 | $108.0K |
| Staley Capital Advisers Inc | 10,000 | $95.9K |
| Persistent Asset Partners Ltd | 9,421 | $90.3K |
| Skopos Labs, Inc. | 2,718 | $26.1K |
| IFP Advisors, Inc | 11 | $105 |